Late clinical outcomes after implantation of drug-eluting stents coated with biodegradable polymers: 3-Year follow-up of the PAINT randomised trial

EuroIntervention

Volumn 8, Issue 1, 2012, Pages 117-119

  Lemos, Pedro A ^a   Moulin, Bruno ^b   Perin, Marco A ^c   Oliveira, Ludmilla A R R ^d   Arruda, J Airton ^e   Lima, Valter C ^f   Lima, Antonio A G ^g   Caramori, Paulo R A ^h   Medeiros, Cesar R ⁱ   Barbosa, Mauricio R ^j   Brito, Fabio S ^k   Ribeiro, Expedito E ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Hospital Universitário Cassiano Antonio de Moraes   (Brazil)

^c HOSPITAL SANTA MARCELINA   (Brazil)

^d Natal Hospital Center   (Brazil)

^e Hospital Meridional   (Brazil)

^f FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^g Hospital Universitário Walter Cantídio   (Brazil)

^h PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

ⁱ Rede d'Or de Hospitais   (Brazil)

^j Hospital Biocor   (Brazil)

^k Hosp Sao Camilo   (Brazil)

more..

Author keywords

Angioplasty; Atherosclerosis; Biodegradable; Coronary; Drug eluting stents; Randomised clinical trial; Restenosis

Indexed keywords

DRUG CARRIER; PACLITAXEL; POLYCAPROLACTONE; POLYGLACTIN; POLYLACTIC ACID; POLYMER; POVIDONE; RAPAMYCIN; SUPRALIMUS; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BARE METAL STENT; BIODEGRADABLE IMPLANT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG COATING; DRUG EFFICACY; DRUG ELUTING STENT; DRUG RELEASE; FEMALE; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MATERIAL COATING; OUTCOME ASSESSMENT; RISK FACTOR; STENT THROMBOSIS;

EID: 84865514039     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV8I1A18     Document Type: Article

References (5)

1. Lemos PA, Moulin B, Perin MA, Oliveira LA, Arruda JA, Lima VC, Lima AA, Caramori PR, Medeiros CR, Barbosa MR, Brito FS, Jr., Ribeiro EE, Martinez EE; PAINT trial investigators. Randomized evaluation of two drug-eluting stents with identical metallic platform and biodegradable polymer but different agents (paclitaxel or sirolimus) compared against bare stents: 1-year results of the PAINT trial. Catheter Cardiovasc Interv 2009;74:665-73.
2. Byrne RA, Iijima R, Mehilli J, Pinieck S, Bruskina O, Schömig A, Kastrati A. Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. JACC Cardiovasc Interv. 2009;2:291-9.
3. Garg S, Sarno G, Serruys PW, de Vries T, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, Corti R, Wijns W, Morice MC, Di Mario C, van Geuns RJ, Eerdmans P, van Es GA, Meier B, Jüni P, Windecker S. The twelve-month outcomes of a biolimus eluting stent with a biodegradable polymer compared with a sirolimus eluting stent with a durable polymer. EuroIntervention. 2010;6:233-9.
4. Lemos PA, Moulin B, Perin MA, Oliveira LA, Arruda JA, Lima VC, Lima AA, Caramori PR, Medeiros CR, Barbosa MR, Brito FS, Jr., Ribeiro EE, Martinez EE; PAINT study. Rationale and design for the PAINT randomized trial. Arq Bras Cardiol. 2009;93:547-53, 590-7.
5. Serruys PW, Daemen J. Are drug-eluting stents associated with a higher rate of late thrombosis than bare metal stents? Late stent thrombosis: a nuisance in both bare metal and drug-eluting stents. Circulation. 2007;115:1433-9; discussion 1439.